Exact Sciences Corp. (Nasdaq:EXAS) today announced its financial results for the quarter ended Sept. 30, 2014.
Exact reported total revenues of $0.0 million for the third quarter of 2014, compared to $1.0 million for the third quarter of 2013. Total revenues for the nine months ended Sept. 30, 2014, were $0.3 million, compared to $3.1 million during the nine months ended Sept. 30, 2013. The company’s revenue had been comprised of the non-cash amortization of up-front license fee payments paid to it by Genzyme Corp. These payments were amortized over a five-year collaboration period that ended in January 2014.
Help employers find you! Check out all the jobs and post your resume.
